Login to Your Account



AMD shark therapy beached, Street paddles Ohr; Kala sign language due to gesture FDA

By Randy Osborne
Staff Writer

Friday, January 5, 2018

Wedbush Securities analyst Liana Moussatos called top-line results from two trials by Kala Pharmaceuticals Inc. "the best phase III dry eye data that I've seen," though not everyone seemed as enthusiastic about the outcomes with KPI-121 0.25 percent vs. placebo.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription